SILVER-COATED ENDOTRACHEAL TUBE

Clinically proven to reduce the incidence In a large, multi-center, prospective, randomized, single-blinded, controlled clinical trial involving 2003 patients, Agento® I.C. silver-coated endotracheal tube was clinically proven to reduce the incidence of microbiologically confirmed ventilator- associated pneumonia (VAP) in patients intubated for $24 hours and significantly delayed VAP onset. Patients Intubated >24 Hours Time (days) More importantly, Agento") I.C. silver-coated endotracheal tube was shown to significantly reduce microbiologically confirmed VAP by 48% within the first 10 days of...

Advanced silver hydrophilic coating technology: Proven against the most prevalent VAP pathogens Hydrophilic Polymer Coating with Silver Nanotechnology Incidence of Common VAP Microorganisms Colloidal Silver particles hydrophilic polymer Steady release of silver ions from inner and outer surface Silver ions penetrate Outer lumen Staphylococcus Methicillin-resistant Pseudomonas Acinetobacter aureus S aureus aeruginosa baumonnii Focused on patients at highest risk for developing VAP Potential Surgical Procedures Patient Related Risk Factors' ■ Organ System Failure Index >2

Advance your current VAP prevention methods with Agent©® I.C.® silver-coated endotracheal tube: ■ Clinically proven to reduce microbiologically confirmed VAP ■ Proven against the most prevalent VAP pathogens including resistant organisms ■ Complement your VAP prevention strategy with minimal user Agento" I.C. Silver-Coated Endotracheal Tubes High Volume Low Pressure Cuff li Bonten MJ. Kotlef MH. Hall JB. Risk factors for vertilator-associated pneumonia: from epidemiology to patient management. Clin Infect Dis. 2004:38:1141- 2. Rello J. Ollendorf DA. Oster G. et al. Epidemiology and outcomes of...